School of Medicine
Showing 1-100 of 140 Results
-
Ranjana Advani
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly Interests Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology. -
Ash A. Alizadeh, MD/PhD
Associate Professor of Medicine (Oncology)
Current Research and Scholarly Interests My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials. -
Douglas W. Blayney
Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Improving the quality of cancer care at Stanford, in our network of care, and nationally
-
Nam Quoc Bui
Clinical Assistant Professor, Medicine - Oncology
Bio Dr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in the Sarcoma and Developmental Therapeutics programs. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies.
-
Robert W. Carlson
Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.
-
Jennifer Caswell-Jin
Instructor, Medicine - Oncology
Current Research and Scholarly Interests My research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.
-
Curtis R. Chong, MD, PhD, MPhil, FACP
Clinical Assistant Professor, Medicine - Oncology
Bio Dr. Chong was recruited to Stanford from the Memorial Sloan Kettering (MSK) Cancer Center, where he led MSK's launch of the early drug development and immunotherapy clinical trials program in New Jersey. At MSK, Dr. Chong was a member of the gastrointestinal oncology service and was one of two MSK physicians in New Jersey who specialized in treating melanoma. Prior to joining MSK, Dr. Chong was a member of the thoracic oncology service at the Dana-Farber Cancer Institute and an attending physician at the Massachusetts General Hospital and Brigham and Women's Hospital, all ailiates of Harvard Medical School.
Dr. Chong completed his categorical residency in internal medicine at the Massachusetts General Hospital/Harvard Medical School, his oncology fellowship at the Dana-Farber Cancer Institute, and is board-certified in internal medicine and medical oncology. He has received research support from the American Society of Clinical Oncology (Young Investigator Award), Uniting Against Lung Cancer, and the American Cancer Society. Dr. Chong has been published in the New England Journal of Medicine, Nature, Nature Medicine, Nature Chemical Biology, JAMA Oncology, and his research on drug discovery has been featured in the New York Times and Popular Science.
Born and raised in Honolulu where he attended public schools, Dr. Chong sang in the Honolulu Boy Choir, and was the 1993 Honolulu Star Bulletin Newspaper Boy of the Year. He received his A.B. in biochemical sciences from Harvard University magna cum laude followed by an M.Phil. in Chemistry with Sir Alan Fersht at the University of Cambridge (Emmanuel College). He then received his MD and PhD in pharmacology from The Johns Hopkins University School of Medicine.
An intrepid traveler and avid long-distance runner, Dr. Chong has visited 54 countries and completed 126 marathons in all 50 states, 18 countries, and 6 on continents. -
Gilbert Chu
Professor of Medicine (Oncology) and of Biochemistry
Current Research and Scholarly Interests After shuttering the wet lab, we have focused on: a point-of-care device to measure blood ammonia and prevent brain damage; a human protein complex that juxtaposes and joins DNA ends for repair and V(D)J recombination; and strategies for teaching students and for reducing selection bias in educational programs.
-
Michael F. Clarke, M.D.
Karel H. and Avice N. Beekhuis Professor in Cancer Biology
Current Research and Scholarly Interests Dr. Clarke maintains a laboratory focused on two areas of research: i) the control of self-renewal of normal stem cells and diseases such as cancer and hereditary diseases; and ii) the identification and characterization of cancer stem cells. His laboratory is investigating how perturbations of stem cell regulatory machinery contributes to human disease. In particular, the laboratory is investigating epigenetic regulators of self renewal, the process by which stem cells regenerate themselves.
-
Carla Nacif Coelho
Affiliate, Medicine - Med/Oncology
Bio Experienced Clinical Trials (CTs) Specialist certified by Berkeley University> Earned my Bachelors of Medicine from UFMG and MBA from IBMEC bothe in Brazil. I am currently working in the Oncology Department at VA with full range of responsibilities from leading the CTs regulatory submissions to CTs initiation and execution. I enjoy hiking, staying in contact with nature and gardening.
-
A. Dimitrios Colevas
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) at the Stanford University Medical Center
Current Research and Scholarly Interests Multi- modality treatment of Head and Neck Cancer
Phase 1 clinical trials -
Christina Curtis
Associate Professor of Medicine (Oncology) and of Genetics
Current Research and Scholarly Interests The Curtis laboratory is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.
-
Millie Das
Clinical Associate Professor, Medicine - Oncology
Bio Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.
-
George Duran
Cancer Biologist and Laboratory Manager, Medicine - Med/Oncology
Current Role at Stanford Cancer biologist specializing in the development of novel chemotherapeutic agents and in mechanisms of drug resistance. Current research ranges from molecular studies to further understand the heterogeneity of T-cell lymphomas, to translational studies of molecular determinants of therapeutic response, and clinical trials that use the body’s immune system to fight cancer cells.
Original research contributions have resulted in the authorship of over eighty publications. -
Alice C. Fan
Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly Interests My laboratory investigates how oncogenes initiate and sustain tumorigenesis. I have developed model systems whereby I can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, I have generated a conditional model system for MYC-induced tumors. I have shown that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation.
-
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Current Research and Scholarly Interests Clinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.
-
Jessica Foran, MSN, NP, RN, ANP-BC, WHNP-BC
Affiliate, Medicine - Med/Oncology
Bio Jessica Foran, MSN, NP, RN, ANP-BC, WHNP-BC is an advanced practice provider who specializes in breast medical oncology at the Stanford Women's Cancer Center. She graduated with her Adult Health Nurse Practitioner (ANP) and Women's Health Nurse Practitioner (WHNP) degrees from MGH Institute of Health Professions and her Bachelors of Science in Nursing (BSN) degree from Johns Hopkins University School of Nursing. Jessica Foran has special interest in breast oncology, clinical research, survivorship, and reproductive health.
-
James Ford
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly Interests Mammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
-
Kristen N Ganjoo
Associate Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Giant cell tumor of the bone
Gastrointestinal stromal tumors
Soft tissue sarcoma
Osteosarcoma -
Joshua Gruber
Instructor, Medicine - Oncology
Bio Dr. Joshua Gruber is an Instructor of Medicine in the division of Medical Oncology at Stanford University Medical Center. He received his Bachelors of Arts, Summa Cum Laude, in biochemistry and physics from the University of Pennsylvania in 2001. He then graduated from the Medical Scientist Training Program at the University of Pennsylvania where he performed doctoral studies in cancer biology and biochemistry. He completed internship and residency in Internal Medicine at Stanford, then was a Clinical Fellowship in Medical Oncology and also a Postdoctoral Fellow in Genetics at Stanford, working in the laboratory of Michael Snyder on integrative genomics of hereditary breast cancer. He is currently has a clinical focus on treating patients with metastatic breast cancer and triple-negative breast cancer and conducts clinical trials on novel therapeutics for these diseases. His laboratory research interests include the molecular biology of breast cancer initiation, the intersection of tumor immunology with cancer growth pathways and the development of molecular tools to interrogate neoplastic tissues.
-
Neel K. Gupta
Clinical Assistant Professor, Medicine - Oncology
Current Research and Scholarly Interests I have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.
-
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
Bio Dr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He currently serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He also collaborates with campus laboratories to help develop new biomarker and treatment technologies. Dr. Heestand is a member of the ECOG-ACRIN gastrointestinal committee and serves as a representative to the NCI Hepatobiliary Task Force. He is also the director of the Stanford Medical Oncology Fellowship Program.
Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.
Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read. -
Christian Hoerner
Basic Life Res Scientist, Medicine - Med/Oncology
Current Role at Stanford Staff Scientist and Lab Manager, Alice Fan Lab
-
Sandra Horning
Professor of Medicine, Emerita
Current Research and Scholarly Interests Clinical Interests: Hodgkin's disease and non-Hodgkin's lymphoma. Research Interests: clinical trials in Hodgkin's disease and malignant lymphoma including high dose therapy and autografting, complications of cytotoxic therapy, novel therapeutics, and clinicopathologic correlations.
-
Robert Hsieh
Adjunct Clinical Assistant Professor, Medicine - Oncology
Bio Robert W. Hsieh, M.D. Ph.D. is a medical oncologist who specializes in the treatment of prostate cancer, bladder cancer, kidney (renal) cancer and testicular cancer as a member of Stanford's multi-disciplinary Urologic Cancer Program. Dr. Hsieh obtained his M.D. and Ph.D. degrees at the University of Chicago (Pritzker School of Medicine) and subsequently came to Stanford to complete his Internal Medicine residency and Hematology and Oncology fellowship training (with a clinical focus on genitourinary cancers).
Dr. Hsieh has also had extensive experience in basic lab research (cancer stem cells, target identification and validation, pre-clinical drug discovery) having done post-doctoral work in the Clarke Lab in the Institute for Stem Cell Biology and Regenerative Medicine. He is currently involved in early phase clinical trials in immuno-oncology in industry. -
Haruka Itakura
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Bio Dr. Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine and practicing oncologist at the Stanford Cancer Center with background in biomedical informatics. She is a physician-scientist whose research mission is to drive medical advances at the intersection of cancer and data science research. Specifically, she aims to innovate state-of-the-art technologies to extract clinically useful knowledge from heterogeneous multi-scale biomedical data to improve diagnostics and therapeutics in cancer. She is a board-certified hematologist-oncologist and informaticist with specialized training in basic science, health services, and translational research. Her clinical background in oncology and PhD training in Biomedical Informatics position her to develop and apply data science methodologies on heterogeneous, multi-scale cancer data to extract actionable knowledge that can improve patient outcomes. Her ongoing research to develop and apply cutting-edge knowledge and skills to pioneer new robust methodologies for analyzing cancer big data is being supported by an NIH K01 Career Development Award in Biomedical Big Data Science. Her research focuses on developing and applying machine learning frameworks and radiogenomic approaches for the integrative analysis of heterogeneous, multi-scale data to accelerate discoveries in cancer diagnostics and therapeutics. Projects include prediction modeling of survival and treatment response, biomarker discovery, cancer subtype discovery, and identification of new therapeutic targets.
-
Charlotte D. Jacobs M.D.
Drs. Ben and A. Jess Shenson Professor in the School of Medicine, Emerita
Current Research and Scholarly Interests Clinical Interests: general oncology, sarcomas. Research Interests: clinical trials in solid tumors.
-
Hanlee P. Ji
Associate Professor of Medicine (Oncology) and, by courtesy, of Electrical Engineering
Current Research and Scholarly Interests Cancer genomics and genetics, translational applications of next generation sequencing technologies, development of molecular signatures as prognostic and predictive biomarkers in oncology, primary genomic and proteomic technology development, cancer rearrangements, genome sequencing, big data analysis
-
Esther M. John
Professor (Research) of Epidemiology and Population Health and of Medicine (Oncology)
Current Research and Scholarly Interests Dr. John has extensive expertise in conducting population-based epidemiologic studies and has led as Principal Investigator multiple large-scale studies, including multi-center studies with a study site in the San Francisco Bay Area with its diverse population. Many of her studies and collaborations investigated cancer health disparities. Her research has focused on the role of modifiable lifestyle factors (e.g., body size, physical activity, diet), hormonal factors, early-life exposures, genetic variants, and gene-environment interactions; differences in risk factors by race/ethnicity, breast cancer subtypes, and prostate cancer subtypes; risk factors for familial breast cancer and second primary breast cancer, as well as prognostic factors related to survival disparities.
As Principal Investigator, Dr. John has led a number of studies conducted in the San Francisco Bay Area, including:
- the Northern California site of the Breast Cancer Family Registry, an on-going prospective multi-generational cohort of over 13,000 families established in 1995 at six international sites;
- the Northern California site of the WECARE Study that investigates risk factors for second primary breast cancer;
- the California site of the Breast Cancer Health Disparities Study that investigated genetic variability and breast cancer risk and survival in Hispanic and non-Hispanic white populations in the context of genetic admixture;
- the Breast Cancer Etiology in Minorities (BEM) Study, a pooled analysis of risk factors for breast cancer subtypes in racial/ethnic minorities;
- the San Francisco Bay Area Breast Cancer Study, a population-based case-control study in nearly 5,000 Hispanic, African American and non-Hispanic white women that investigated the role of modifiable lifestyle factors and other risk factors;
- the San Francisco Bay Area Prostate Cancer Study, a population-based case-control study of lifestyle and genetic risk factors for advanced and localized disease.
These studies collected and pooled extensive data and biospecimens and continue to support numerous ancillary studies, collaborations and international consortia and have contributed to a better understanding of cancer risk and survival in racial/ethnic minority populations.
Dr. John is also a founding PI of the LEGACY Girls Study, an on-going prospective cohort established in 2011 that investigates early life exposures in relation to pubertal development outcomes, breast tissue characteristics, and behavioral and psychosocial outcomes in the context of having a family history or breast cancer. -
Tyler Johnson
Clinical Assistant Professor, Medicine - Oncology
Bio I grew up hiking in the Wasatch Mountains and, after completing college in Utah, I moved to Philadelphia to attend medical school at the University of Pennsylvania in 2005. After graduating in 2009, I came to Stanford for my general internal medicine internship and residency, was invited to stay as a chief resident in 2012, and then stayed again for oncology/hematology fellowship in 2013 before joining the faculty of the division of oncology in 2016. Here at Stanford I pursue my twin passions of providing excellent clinical care and mentoring the next generation of physicians.
I specialize in the care of patients who have gastrointestinal tumors, including tumors of the pancreas, large and small bowel, liver, and biliary tree. I have experience with rare GI tumors--including both intra and extra hepatic cholangiocarcinoma--and trained under Dr. Pamela Kunz, one of the country's leading experts in the care of patients with neuroendocrine tumors and have thus seen a large number of these patients, as well.
I am lucky to have a first rate medical team by my side consisting of a nurse coordinator, a nurse practitioner, and a physician assistant. We strive together to provide capable, compassionate, responsive care and make the care of our patients our highest priority.
In addition to patient care, I am a devoted medical teacher and have worked over the past five years to elevate the teaching of medicine at Stanford University, where I have taught medical students, residents, and fellows, including conducting a randomized, controlled trial hoping to optimize the way we teach communication skills to nascent physicians.
Fluent in Spanish, I have lived in both Mexico and Argentina and am comfortable in virtually all medical situations conversing fluently in Spanish without an interpreter. I especially enjoy providing care to patients who speak Spanish as a first language. -
Saad A. Khan, MD
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Bio Saad A. Khan, MD is a medical oncologist focused on the treatment of head and neck, thyroid and lung cancers. His research interests include therapeutic clinical trials as well as mechanisms of reducing toxicities that patients experience. His research activities include ongoing clinical trials of targeted and immune therapy in aggressive thyroid malignancies. He is a member of the NRG Head and Neck Committee, the ECOG Head and Neck Core and Thoracic Committees and the National Cancer Institute’s Head and Neck Steering Committee Rare Tumor Task Force.
When not in clinic or the hospital he enjoys spending time with his family and 3 children, hiking and sitting on the beach. -
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Clinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.
-
Daniel Alexander King
Postdoctoral Medical Fellow, Oncology
Bio Daniel Alexander King, MD, PhD (Oncology Fellow)
Originally from Long Island, NY, Dan trained at Cold Spring Harbor Laboratory, the University of Michigan (BS), Wayne State University (MD), the National Human Genome Research Institute (HHMI Research Scholars Program), Cambridge University (PhD), and Columbia University (Internal Medicine Residency). He enjoys mutation hunting in large-scale genomic data. He was most recently involved in an exome sequencing study of 12,000 children with rare disease and their parents, in which he developed new computational tools to identify large genetic aberrations. His mutational spectrum of interest includes uniparental disomy, copy number alterations, and mosaicism. He plans to explore research opportunities riding the intersection of new technology & genomics, such as single cell DNA & RNA sequencing, and circulating tumor DNA.
During oncology fellowship he has developed a passion for pancreatic cancer and specializes in caring for patients with pancreatic cancer in clinic with renowned medical oncologist Dr George Fisher. During fellowship his pancreatic research interests span the spectrum of translational research in pancreatic cancer. Several recent accomplishments include: 1) the development of a pancreatic cancer-specific circulating tumor DNA assay, the development of a pancreatic cancer research database containing thousands of patients who presented to Stanford with pancreatic cancer over the last twenty years, and the development of a large +500 sample biobank consisting of blood samples from generous pancreatic cancer patient study participants. -
Allison W. Kurian, M.D., M.Sc.
Professor of Medicine (Oncology) and of Epidemiology and Population Health at the Stanford University Medical Center
Current Research and Scholarly Interests I aim to improve the outcomes of women's cancers through clinically-oriented research on genetic risk assessment, risk-adapted screening and prevention.
-
David Kurtz
Instructor, Medicine - Oncology
Current Research and Scholarly Interests Implementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.
-
HoJoon Lee
Sr Biomedical Data Scientist, Medicine - Med/Oncology
Current Role at Stanford Senior Data Scientist
-
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
Current Research and Scholarly Interests Clinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.
-
Shoshana Levy
Professor (Research) of Medicine (Oncology)
Current Research and Scholarly Interests Our research focuses on the mechanism of action of tetraspanins, an evolutionary conserved, widely expressed multi-gene family. We study a prototype, CD81, a molecule implicated in the pathogenesis of two major human diseases: hepatitis C virus (HCV) and malaria.
-
Beverly S. Mitchell, M.D.
George E. Becker Professor in Medicine and Professor, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly Interests Beverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.
-
Eric Mou
Postdoctoral Medical Fellow, Oncology
Bio I was born in Oregon and raised in Iowa, where I cultivated my initial interest in science and medicine. I completed my undergraduate degree and medical school at the University of Iowa before heading to Stanford University for my internal medicine residency and oncology fellowship training. I chose this field to try my best in assisting patients during times of great need, and working to understand what is of greatest importance to them as they navigate their unique journey of cancer care. My clinical focus is in the care of patients with lymphoma and other hematologic cancers. My scholarly interests include better understanding the efficacy cancer therapeutics, improving patients' experience as the proceed through treatment, and promoting strength in medical education.
-
Joel Neal, MD, PhD
Associate Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests I am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.
-
Mark Pegram
Susy Yuan-Huey Hung Professor
Current Research and Scholarly Interests Molecular mechanisms of targeted therapy resistance in breast and other cancers
-
Harlan Pinto
Associate Professor of Medicine (Oncology) at the Palo Alto Veterans Affairs Health Care System and of Otolaryngology - Head & Neck Surgery at the Stanford University Medical Center
Current Research and Scholarly Interests Clinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer
-
Kavitha Ramchandran
Clinical Associate Professor, Medicine - Oncology
Current Research and Scholarly Interests My research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.
In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs.
